Handa Pharmaceuticals, Inc. (TPEX:6620)

Market Cap	11.80B +17.4%
Revenue (ttm)	1.62B +71.6%
Net Income	683.16M +50.7%
EPS	4.53 +40.9%
Shares Out	157.33M
PE Ratio	16.55
Forward PE	n/a
Dividend	1.51 (2.01%)
Ex-Dividend Date	n/a

Volume	499,081
Average Volume	420,900
Open	76.80
Previous Close	77.40
Day's Range	74.30 - 76.90
52-Week Range	55.00 - 154.00
Beta	0.84
RSI	26.20
Earnings Date	Apr 24, 2026

About Handa Pharmaceuticals

Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States. The company offers ONCORE, a proprietary drug delivery technology that was developed to improve the patient compliance and safety of the tyrosine kinase inhibitor of oncology drugs; Tascenso ODT for the treatment of multiple sclerosis; and HND-033, HND-039, and HND-027 for oncology diseases. It also provides Quetiapine XR to treat Schizophrenia; Dexlansoprazole DR capsules to treat erosive esophagitis a...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2014
• Employees: 13
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6620

Financial Performance

In 2024, Handa Pharmaceuticals's revenue was 830.67 million, a decrease of -24.92% compared to the previous year's 1.11 billion. Earnings were 472.74 million, a decrease of -34.96%.